



DAFTAR PUSTAKA

- Abate, S.M., Checkol, Y.A., Mantefardo, B., 2021. Global prevalence and determinants of mortality among patients with COVID-19: A systematic review and meta-analysis. *Ann. Med. Surg.* 64, 102204. <https://doi.org/10.1016/j.amsu.2021.102204>
- Abou-Ismail, M.Y., Diamond, A., Kapoor, S., et al., 2020. The hypercoagulable state in COVID-19: Incidence, pathophysiology, and management. *Thromb. Res.* 194, 101–115. <https://doi.org/10.1016/j.thromres.2020.06.029>
- Ackermann, M., Verleden, S.E., Kuehnel C., et al., 2020. Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in COVID-19. *N. Engl. J. Med.* 383,120–128. <https://doi.org/10.1056/NEJMoa2015432>
- Ahmad, F.B., Cisewski, J.A., Minino, A., et al., 2021. Provisional Mortality Data - United States, 2020. *MMWR. Morb. Mortal. Wkly. Rep.* 70, 519–522. <https://doi.org/10.15585/mmwr.mm7014e1>
- Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., ... & Alamares, J. G. (2021). Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. *New England Journal of Medicine*, 384(5),403-416. <https://doi.org/10.1056/NEJMoa2035389>
- Belur, A. D., Mahadesh, K., & Sudhakar, S. K. (2020). Gender disparities in D-Dimer levels and its implications for thromboprophylaxis in COVID-19: a retrospective cohort study. *SN Comprehensive Clinical Medicine*, 2(11), 2183-2187. <https://doi.org/10.1007/s42399-020-00628-6>
- Bikdeli, B., Madhavan, M. V., Jimenez, D., Chuich, T., Dreyfus, I., Driggin, E., ... Parikh, S. A. (2020). COVID-19 and thrombotic or thromboembolic disease: Implications for prevention, antithrombotic therapy, and follow-up. *Journal of the American College of Cardiology*, 75(23), 2950-2973. <https://doi.org/10.1016/j.jacc.2020.04.031>
- Chen, L.Y.C., Hoiland, R.L., Stukas, S., et al., 2020. Confronting the controversy: Interleukin-6 and the COVID-19 cytokine storm syndrome. *Eur. Respir. J.* 56. <https://doi.org/10.1183/13993003.03006-2020>
- Conti, P., Ronconi, G., Caraffa, A., et al, 2020. Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies. *J. Biol. Regul. Homeost. Agents.* <https://doi.org/10.23812/CONTI-E>
- Connors, J. M., & Levy, J. H. (2021). COVID-19 and its implications for thrombosis and anticoagulation. *Blood*, 135(23), 2033–2040. <https://doi.org/10.1182/blood.2020006000>
- Cui, S., Chen, S., Li, X., Liu, S., Wang, F. (2020). Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. *Journal of Thrombosis and Haemostasis*, 18(6), 1421-1424.
- da Rosa M.R., Francelino, L.C., Santos, F.M., et al., 2021. Clinical manifestations of COVID-19 in the general population: systematic review. *Wien. Klin. Wochenschr.* 133, 377–382. <https://doi.org/10.1007/s00508-020-01760-4>
- Dhama, K., Patel, S.K., Kumar, R., et al., 2021. The role of disinfectants and sanitizers during COVID-19 pandemic: advantages and deleterious effects on humans and the environment. *Environ. Sci. Pollut. Res. Int.* 28, 34211–34228. <https://doi.org/10.1007/s11356-021-14429-w>
- Fatima, S., Zafar, A., Afzal, H., et al., (2022). COVID-19 infection among vaccinated and unvaccinated: Does it make any difference?. *PloS one*, 17(7), e0270485. <https://doi.org/10.1371/journal.pone.0270485>
- Favaloro, E.J., 2021. Laboratory testing for suspected COVID-19 vaccine-induced (immune) thrombotic thrombocytopenia. *Int. J. Lab. Hematol.* 43, 559–570. <https://doi.org/https://doi.org/10.1111/ijlh.13629>
- Fazio, S., Vaccariello, M., Affuso, F., 2022. A Case of Adverse Reaction to Booster Dose of COVID-19 Vaccination: Could D-Dimer Elevation Suggest Increased Clotting Risk? *Health (Irvine. Calif.)*. 14, 204–208.<https://doi.org/10.4236/health.2022.142015>.
- Gao, Y., Ding, M., Dong, X., et al., 2021. Risk factors for severe and critically ill COVID-19 patients:A review. *Allergy* 76,428–455.<https://doi.org/https://doi.org/10.1111/all.14657>
- Greinacher, A., Thiele, T., Warkentin, T.E., et al., 2021. Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination. *N. Engl. J. Med.* 384, 2092–2101. <https://doi.org/https://doi.org/10.1056/NEJMoa2132111>



- org/10.1056/NEJMoa2104840
- Gupta, A., Madhavan, M. V., Sehgal, *et al.*, 2020. Extrapulmonary manifestations of COVID-19. *Nat. Med.* 26, 1017–1032. <https://doi.org/10.1038/s41591-020-0968-3>
- Harder, T., Koch, J., Vygen-Bonnet, S., *et al.*, (2021). Efficacy and effectiveness of COVID-19 vaccines against SARS-COV-2 infection: interim results of a living systematic review, 1 January to 14 May 2021. *Euro Surveill*, 26(28): 2100563.
- Hendren, N. S., de Lemos, J. A., Ayers, C. *et al.* "Association of body mass index and age with morbidity and mortality in patients hospitalized with COVID-19: Results from the American Heart Association COVID-19 Cardiovascular Disease Registry." *Circulation* 143, 135–144 (2021). doi:10.1161/CIRCULATIONAHA.120.051936
- Hirabara, S., Serdan, T., Gorjao, R., *et al.*, 2022. SARS-COV-2 Variants: Differences and Potential of Immune Evasion . *Front. Cell. Infect. Microbiol.* .
- Hu, X., Gao, J., Luo, X. *et al.* "Risk factors for mortality of COVID-19 patients in a retrospective single center study in China." *Front. Med.* 7, 498 (2020). doi:10.3389/fmed.2020.00527
- Iba, T., Warkentin, T. E., Thachil, J., *et al.*, (2021). Proposal of the Definition for COVID-19- Associated Coagulopathy. *Journal of clinical medicine*, 10(2), 191. <https://doi.org/10.3390/jcm10020191>
- Jin, J.-M., Bai, P., He, W., *et al.*, 2020. Gender Differences in Patients With COVID-19: Focus on Severity and Mortality. *Front. public Heal.* 8, 152. <https://doi.org/10.3389/fpubh.2020.00152>
- Kaur, R.J., Dutta, S., Bhardwaj, P., *et al.*, 2021. Adverse Events Reported From COVID-19 Vaccine Trials: A Systematic Review. *Indian J. Clin. Biochem.* 36, 427–439. <https://doi.org/10.1007/s12291-021-00968-z>
- Kaytaz, M., Akkaya, E., Gumus, S.N., *et al*, 2022. IgG-RBD Response Due to Inactivated SARS- COV-2 Vaccine: Alteration in D-Dimer and Fibrinogen Concentrations, Association with Comorbidities and Adverse Effects. *Lab. Med.* 53, 590–595. <https://doi.org/10.1093/labmed/lmac047>
- Kearon, C., de Wit, K., Parpia, S., *et al.*, (2019). Diagnosis of Pulmonary Embolism with D-Dimer Adjusted to Clinical Probability. *The New England journal of medicine*, 381(22), 2125– 2134. <https://doi.org/10.1056/NEJMoa1909159>
- Kementerian Kesehatan Republik Indonesia, 2022. Panduan Tatralaksana COVID-19 Edisi ke 4, Edisi 4. ed. Jakarta.
- Kichloo, A., Dettloff, K., Aljadah, M., *et al*, 2020. COVID-19 and Hypercoagulability: A Review. *Clin. Appl. Thromb. Off. J. Int. Acad. Clin. Appl. Thromb.* 26, 1076029620962853. <https://doi.org/10.1177/1076029620962853>
- Klok, F.A., Pai, M., Huisman, M. V, *et al*, 2022. Vaccine-induced immune thrombotic thrombocytopenia. *Lancet Haematol.* 9, e73–e80. [https://doi.org/10.1016/S2352-3026\(21\)00306-9](https://doi.org/10.1016/S2352-3026(21)00306-9)
- Koçak, C., 2021. COVID-19 Isolation and Contact Tracing with Country Samples: A Systematic Review. *Iran. J. Public Health* 50, 1547–1554. <https://doi.org/10.18502/ijph.v50i8.6800>
- Konings, F., Perkins, M.D., Kuhn, J.H., *et al.*, 2021. SARS-COV-2 Variants of Interest and Concern naming scheme conducive for global discourse. *Nat. Microbiol.* 6, 821–823. <https://doi.org/10.1038/s41564-021-00932-w>
- Korang, S.K., von Rohden, E., Veroniki, A.A., *et al.*, 2022. Vaccines to prevent COVID- 19: A living systematic review with Trial Sequential Analysis and network meta- analysis of randomized clinical trials. *PLoS One* 17, e0260733–e0260733. <https://doi.org/10.1371/journal.pone.0260733>
- Levi, M., & Thachil, J. (2020). Coagulation abnormalities and thrombosis in patients with COVID- 19. *The Lancet Haematology*, 7(6), e438–e440. [https://doi.org/10.1016/S2352-3026\(20\)30145-9](https://doi.org/10.1016/S2352-3026(20)30145-9)
- Li, X., Zhong, X., Wang, Y., *et al*, 2021. Clinical determinants of the severity of COVID-19: A systematic review and meta-analysis. *PLoS One* 16, e0250602–e0250602. <https://doi.org/10.1371/journal.pone.0250602>
- Li, Z. *et al.*, 2021. Characterization of SARS-COV-2 -Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting. *Frontiers in Immunology*, 12. <https://doi.org/10.3389/fimmu.2021.802858>.
- Lippi, G., & Favaloro, E. J. (2018). Laboratory hemostasis: from biology to the bench. *Clinical chemistry and laboratory medicine*, 56(7), 1035–1045. <https://doi.org/10.1515/cclm-2017-1205>



- Lippi, G., Mullier, F. & Favoloro, E. (2022). D-Dimer: old dogmas, new (COVID-19) tricks. *Clinical Chemistry and Laboratory Medicine (CCLM)*. <https://doi.org/10.1515/cclm-2022-0633>
- Mani, A., Ojha, V., 2022. Thromboembolism after COVID-19 Vaccination: A SystematicReview of Such Events in 286 Patients. *Ann. Vasc. Surg.* 84, 12–20.e1. <https://doi.org/10.1016/j.avsg.2022.05.001>
- Mascellino, M.T., Di Timoteo, F., De Angelis, M., et al., 2021. Overview of the Main Anti-SARS-CoV-2 Vaccines: Mechanism of Action, Efficacy and Safety. *Infect. Drug Resist.* 14, 3459–3476. <https://doi.org/10.2147/IDR.S315727>
- Moghadas, S. M., Vilches, T. N., Zhang, K., et al., (2021). The Impact of Vaccination on Coronavirus Disease 2019 (COVID-19) Outbreaks in the United States. *Clin Infect Dis*, 73(12): 2257-64.
- Monagle, P., Ng, A.P., Linden, M., et al., 2021. Vaccine-induced immune thrombosis and thrombocytopenia syndrome following adenovirus-vectorized severe acute respiratorysyndrome coronavirus 2 vaccination: a novel hypothesis regarding mechanisms andimplications for future vaccine development. *Immunol. Cell Biol.* 99, 1006–1010. <https://doi.org/https://doi.org/10.1111/imcb.12505>
- Moore, P., Esmail, F., Qin, S., et al, 2022. Hypercoagulability of COVID-19 and Neurological Complications: A Review. *J. stroke Cerebrovasc. Dis. Off. J. Natl. Stroke Assoc.* 31, 106163. <https://doi.org/10.1016/j.jstrokecerebrovasdis.2021.1063>
- Muir, K.-L., Kallam, A., Koepsell, S.A., et al, 2021. Thrombotic Thrombocytopenia after Ad26.COV2.S Vaccination. *N. Engl. J. Med.* <https://doi.org/10.1056/NEJMc2105869>
- Ortiz-Prado, E., Simbaña-Rivera, K., Gómez-Barreno, L., et al, 2020. Clinical, molecular, and epidemiological characterization of the SARS-CoV-2 virus and the CoronavirusDisease 2019 (COVID-19), a comprehensive literature review. *Diagn. Microbiol. Infect. Dis.* 98, 115094. <https://doi.org/10.1016/j.diagmicrobio.2020.115094>
- Pascarella, G., Strumia, A., Piliego, C., et al., 2020. COVID-19 diagnosis and management:a comprehensive review. *J. Intern. Med.* 288, 192–206. <https://doi.org/10.1111/joim.13091>
- Peyvandi, F., Artoni, A., Novembrino, C., et al., 2021. Hemostatic alterations in COVID-19. *Haematologica* 106, 1472–1475. <https://doi.org/10.3324/haematol.2020.262634> Poudel, A., Poudel, Y., Adhikari, A., et al, 2021. D-Dimer as a biomarker for assessmentof COVID-19 prognosis: D-Dimer levels on admission and its role in predicting disease outcome in hospitalized patients with COVID-19. *PLoS One* 16, e0256744. <https://doi.org/10.1371/journal.pone.0256744>
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., ... & Perez, J. L. (2020). Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *NewEnglan Journal of Medicine*, 383(27), 2603-2615. <https://doi.org/10.1056/NEJMoa2034577>
- Pulivarthi, S., & Gurram, M. K. (2014). Effectiveness of D-Dimer as a screening test for venous thromboembolism: an update. *North American journal of medical sciences*, 6(10), 491–499. <https://doi.org/10.4103/1947-2714.143278>
- Robert-Ébadi, H., Righini, M., 2020. D-Dimer: Well beyond diagnosis! *J. Med. Vasc.* <https://doi.org/10.1016/j.jdmv.2020.06.006>
- Sadeghi-Haddad-Zavareh, M., Bayani, M., Shokri, M., et al., 2021. C-Reactive Protein asa Prognostic Indicator in COVID-19 Patients. *Interdiscip. Perspect. Infect. Dis.* 2021, 5557582. <https://doi.org/10.1155/2021/5557582>
- Sathe, P.M., Patwa, U.D., 2014. D D-Dimer in acute care. *Int. J. Crit. Illn. Inj. Sci.* 4, 229–232. <https://doi.org/10.4103/2229-5151.141435>
- Satuan Tugas Penanganan COVID-19, 2022. Peta Sebaran COVID-19 di Indonesia [WWW Document]. Kementeri. Kesehat. RI. URL [https://covid19.go.id/peta- sebaran](https://covid19.go.id/peta-sebaran)
- Singhal, T., 2020. A Review of Coronavirus Disease-2019 (COVID-19). *Indian J. Pediatr.* 87, 281–286. <https://doi.org/10.1007/s12098-020-03263-6>
- Smadja, D.M., Yue, Q.-Y., Chocron, R., et al, 2021. Vaccination against COVID-19: insight from arterial and venous thrombosis occurrence using data from VigiBase. *Eur. Respir. J.* <https://doi.org/10.1183/13993003.00956-2021>
- Suh, Y. J., Hong, H., Ohana, M., Bompard, F., Revel, M. P., Valle, C., Gervaise, A., Poissy, J., Susen, S., Hékimian, G., Wohlfahrt, J., Mirault, T., Socie, G., Timsit, J.F., Roux, C., & Delrue, M. (2021). Pulmonary Embolism and Deep Vein Thrombosis in COVID-19: A



- Systematic Review and Meta-Analysis. Radiology, 298(2), E70–E80.
<https://doi.org/10.1148/radiol.2020201955>
- Tan, D.H.S., Chan, A.K., Jüni, P., et al., 2021. Post-exposure prophylaxis against SARS-CoV-2 in close contacts of confirmed COVID-19 cases (CORIPREV): study protocol for a cluster-randomized trial. Trials 22, 224.
<https://doi.org/10.1186/s13063-021-05134-7>
- Tang, N., Li, D., Wang, X., et al., 2020. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J. Thromb. Haemost. 18, 844–847. <https://doi.org/10.1111/jth.14768>
- Thachil, J., Lippi, G., & Favaloro, E. J. (2017). D-Dimer Testing: Laboratory Aspects and Current Issues. Methods in molecular biology (Clifton, N.J.), 1646, 91–104.
https://doi.org/10.1007/978-1-4939-7196-1_7
- Troiano, G. & Nardi, A. (2021). Vaccine hesitancy in the era of COVID-19. *Public Health*, 194: 245–51.
- Tsai, P.-H., Lai, W.-Y., Lin, Y.-Y., et al., 2021. Clinical manifestation and disease progression in COVID-19 infection. J. Chinese Med. Assoc. 84.
- Wang, C., Wang, Z., Wang, G., et al., 2021. COVID-19 in early 2021: current status and looking forward. Signal Transduct. Target. Ther. 6, 114. <https://doi.org/10.1038/s41392-021-00527-1>
- Wang, Y.-H., Wu, C.-C., Bai, C.-H., et al., 2021. Evaluation of the diagnostic accuracy of COVID-19 antigen tests: A systematic review and meta-analysis. J. Chinese Med. Assoc. 84.
- World Health Organization (WHO). (2022). COVID-19 vaccines: safety surveillance manual. Diakses pada 24 Februari 2022, dari https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccine_safety_surveillance_manual-2021.1
- Wong, R.S.Y., 2021. Inflammation in COVID-19: from pathogenesis to treatment. Int. J. Clin. Exp. Pathol. 14, 831–844.
- Yuki, K., Fujiogi, M., Koutsogiannaki, S., 2020. COVID-19 pathophysiology: A review. Clin. Immunol. 215, 108427. <https://doi.org/10.1016/j.clim.2020.108427>
- Zhu, J., Zhong, Z., Ji, P., et al., 2020. Clinicopathological characteristics of 8697 patients with COVID-19 in China: a meta-analysis. Fam. Med. community Heal. 8, e000406–e000406. <https://doi.org/10.1136/fmch-2020-000406>
- Zhang, L., Feng, X., Zhang, D., Jiang, C., Mei, H., Wang, J., Zhang, C., Li, H., Xia, X., Kong, S., Liao, J., Jia, H., Pang, X., Song, Y., Tian, Y., Wang, B., Wu, C., Yuan, H., Zhang, Y., Yang, Y. (2020). Deep Vein Thrombosis in Hospitalized Patients with COVID-19 in Wuhan, China: Prevalence, Risk Factors, and Outcome. Circulation, 142(2), 1